Latest news with #EUlegislation
Yahoo
4 days ago
- Business
- Yahoo
MySize Reports Second Quarter 2025 Financial Results; Narrows Losses and Positions Percentil as a Leader in Europe's Circular Fashion Economy
New acquisition taps into EU's regulatory push for sustainable apparelCompany investing in market capture as EU legislation reshapes apparel industry AIRPORT CITY, Israel , Aug. 15, 2025 /PRNewswire/ -- With the acquisition and launch of Percentil, MySize has strengthened its position in Europe's rapidly evolving circular fashion economy — a market transformation driven by new EU legislation mandating durability, repairability, recyclability, and traceability in apparel. "We are focused on building long-term value while delivering operational progress each quarter," said Ronen Luzon, Founder and CEO of MySize. "The EU is rewriting fashion's rulebook. Percentil is designed to help brands comply with these new standards and unlock new opportunities for growth." Q2 and H1 2025 Highlights Revenue: $2.0 million in the three months ended June 30, 2025, up 2% year-over-year (YoY), primarily due to the addition of Percentil; $3.5 million in the six months ended June 30, 2025, down 30% YoY, attributable to a decrease in Orgad sales due to market changes. Gross Profit: $1.1 million in the three months ended June 30, 2025, up 14% YoY; $1.5 million in the six months ended June 30, 2025, down 30% YoY Operating Loss: $586,000 in the three months ended June 30, 2025, a 49% improvement from the corresponding period in 2024; $1.6 million in the six months ended June 30, 2025, a 25% improvement from the corresponding period in 2024 Cash Position: $4.28 million as of June 30, 2025, with $2.90 million in inventory. Percentil Contribution: $180,000 in revenue since May acquisition, with integration milestones ahead of schedule. Orgad Optimization: Transition to Fulfillment by Amazon (FBA) lowered logistics costs and improved delivery efficiency. Why Percentil Changes the Game Percentil operates in Spain and across Europe, directly in the path of the EU's Circular Economy Action Plan and Extended Producer Responsibility (EPR) for textiles. As legislation forces brands to manage the entire lifecycle of their products — including take-back, recycling, and repair — Percentil provides a ready-made platform for compliance and is not an optional trend. It is a structural shift in the fashion industry, backed by regulation and consumer demand for sustainability. Percentil's capabilities in AI-powered product matching, garment grading, and logistics integration position it as the go-to solution for brands navigating this change. CEO Commentary "Some companies see regulation as a hurdle. We see it as the competitive advantage," Luzon added. "In five years, we believe European fashion resale will not be a niche — it will be the infrastructure of the industry. We intend Percentil to be at the center of that infrastructure, enabling brands to comply, delight customers, and operate profitably in a circular economy." Strategic Highlights Three Complementary Segments – SaaS sizing solutions (MySizeID, Naiz Fit), fashion & equipment e-commerce (Orgad), and apparel resale (Percentil). Regulatory Tailwind Alignment – Designed to meet EPR, eco-design, and Digital Product Passport requirements as they roll out across Europe. Technology Differentiation – FirstLook Smart Mirror and Smart Catalog enhance both resale and retail experiences. Looking Ahead MySize is investing in long-term market capture in the European resale space, leveraging its triple-revenue model to create operational synergies and recurring cash flow. The company expects Percentil's contribution to accelerate in the second half of 2025, driven by brand partnerships and regulatory compliance demand. About MySize, Inc. MySize, Inc. (Nasdaq: MYSZ), an AI-powered fashion technology company operating across sizing solutions, e-commerce, and circular fashion platforms. Its portfolio includes Orgad, a fashion and equipment e-commerce business, and Percentil, a European resale platform operating at the forefront of the continent's circular fashion legislation. MySize's solutions empower retailers to increase conversion rates, boost average order value, and reduce returns, contributing to more sustainable commerce. The company's innovations include the FirstLook Smart Mirror and Smart Catalog for in-store and online personalization. Learn more at We routinely post information that may be important to investors in the Investor Relations section of our website. Follow us on Facebook, LinkedIn, Instagram, and X (formerly known as Twitter). For more information, visit Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements related to strategic and business plans, technology, relationships, objectives and expectations for its business, growth. These statements are identified by the use of the words "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" and similar expressions that are intended to identify forward-looking statements. All forward-looking statements speak only as of the date of this press release. You should not place undue reliance on these forward-looking statements. Although we believe that our plans, objectives, expectations and intentions reflected in or suggested by the forward-looking statements are reasonable, we can give no assurance that these plans, objectives, expectations or intentions will be achieved. Forward-looking statements involve significant risks and uncertainties (some of which are beyond our control) and assumptions that could cause actual results to differ materially from historical experience and present expectations or projections. Actual results may differ materially from those in the forward-looking statements and the trading price for our common stock may fluctuate significantly. Forward-looking statements also are affected by the risk factors described in the Company's filings with the U.S. Securities and Exchange Commission. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Investor ContactOren Elmaliah, CFOir@ Logo - View original content: SOURCE My Size Inc.
CNA
10-07-2025
- Business
- CNA
EU's top court adviser sides with Italy in Meta Platforms dispute
BRUSSELS :EU member states have the right to impose their own measures to strengthen the position of publishers in their dealings with large online platforms as long as these do not undermine freedom of contract, an adviser to the EU's highest court said on Thursday. The European Union's Court of Justice (CJEU) is handling a dispute between Facebook owner Meta and the Italian communications authority AGCOM, over a fee the U.S. tech giant has to pay publishers in Italy for using snippets of their news articles. Meta had questioned whether such national measures are compatible with rights already granted to publishers under the EU copyright legislation. But CJEU Advocate General Maciej Szpunar said the rights the EU had intended to give to publishers went beyond only allowing them to oppose the use of their material if they were not paid for them. "Their purpose is to establish the conditions under which those publications are actually used, while allowing publishers to receive a fair share of the revenues derived by platforms from that use," he said. "The limitations introduced pursue a public interest recognised by the EU legislature: strengthening the economic viability of the press, a key pillar of democracy." However Szpunar said the Italian regulator should keep in mind contractual freedom. "The powers conferred on AGCOM – including the definition of benchmark criteria for determining remuneration, the resolution of disagreements and the monitoring of the obligation to provide information – are permissible if they are limited to assistance and do not deprive the parties of their contractual freedom," he said. The court, which usually follows the majority of recommendations by the advocate-general, will rule in the coming months. The case is C-797/23 Meta Platforms Ireland (Fair compensation).
BreakingNews.ie
15-06-2025
- Politics
- BreakingNews.ie
MEPs to vote on legislation to criminalise AI-generated child sexual abuse material
MEPs will vote on Tuesday to update EU-wide legislation on child sexual abuse crimes to account for technological advances and to improve victim support. The legislation would revise the definitions of crimes to take account of new technological realities, raise certain maximum punishments, and provide better support to victims. Advertisement The draft law criminalises child sexual abuse instruction manuals and artificially-created deepfake imagery. In the draft position adopted by the Committee on Civil Liberties, Justice and Home Affairs, MEPs proposed the removal of limitations on the length of time victims have to report a crime, so they have enough time to come forward with their experiences. MEPs also want to introduce a new definition of consent for children who are above the age of sexual consent. In addition to the directive, a separate regulation on child sexual abuse is also being discussed by lawmakers. Parliament adopted its position on the draft regulation in 2023; legislative talks can begin once the European Council reaches a common position
Yahoo
19-05-2025
- Business
- Yahoo
EU (European Union)/United Kingdom Proposed Pharmaceutical Legislation Changes Training Course (ONLINE EVENT: May 19, 2025)
Dublin, May 19, 2025 (GLOBE NEWSWIRE) -- The "EU (European Union) Proposed Pharmaceutical Legislation Changes Training Course" training has been added to offering. The course is designed primarily for regulatory affairs personnel, however, it will also be of value to those who interact with the regulatory affairs function and would benefit from an understanding of action timelines and strategic factors in obtaining and maintaining marketing authorisations. In the dynamic and highly regulated field of pharmaceuticals, staying abreast of regulatory affairs is crucial for ensuring compliance, maintaining market authorisations, and effectively managing drug development and post-approval obligations. Navigating the complexities of regulatory processes, particularly in the context of evolving legislation, can be challenging. This is where a comprehensive understanding of pharmaceutical regulatory affairs is invaluable. It is important that companies are aware of proposed changes to pharmaceutical legislation in the EU and the potential impact on company planning and strategy. The EU (European Union) on 23rd April 2023 published proposed changes to pharmaceutical legislation. Discussions between the EU Commission, the MS (Member State) and all stakeholders are ongoing. Review by the European Parliament and the EU Council is required before ratification and implementation which is unlikely to be implemented before 2025/2026. Developing products is a lengthy process and the cost of developing new and modified products is increasing. It is therefore important to be aware of procedures and timelines for obtaining marketing authorisations and importantly to know what if any post approval data and marketing protection will be available. The programme will cover current pharmaceuticals legislation in the EU. The background to the proposed changes in pharmaceuticals legislation will be outlined with discussed in the relevant sections including proposed changes to procedures for obtaining marketing authorisation in the EU, and post-authorisation data and marketing protection criteria and periods. The UK is no longer a member of the EU but knowledge of interactions and collaboration with the EU and other regulatory agencies are essential for obtaining and maintaining marketing authorisations in the UK. The format will provide opportunities for discussion and for sharing of concerns and experiences with our expert trainer and other delegates. Benefits of attending Understand the legal basis of the EU regulatory environment Discuss the background to and the proposed changes to EU Pharmaceuticals legislation Review current and proposed procedures for applying for a marketing authorisation in the EU/EEA and in the UK Consider post-authorisation data and marketing protection Learn about proposed changes to the EMA responsibilities and function Certifications: CPD: 3 hours for your records Certificate of completion Who Should Attend: Regulatory affairs Project management Business planning Commercial management Labelling and artwork Medical information Manufacturing and QA Key Topics Covered: Introduction of presenter and participants Aim of course Background Background to proposed EU legislation changes Proposed changes to EU pharmaceuticals legislation Pre-submission Development advice Discussion re adaptive procedures Submission procedures EU procedure for obtaining marketing authorisation and proposed changes The EMA Centralised Procedure (CP) The Co-ordination Group Decentralised Procedure (DCP) Submission procedures (continued) Mutual Recognition Procedure (MRP) National procedures Including UK procedures Post-authorisation Post-authorisation data and marketing protection and proposed changes Post-authorisation obligations and proposed changes Institutional and wider issues Product supply One Health Environmental protection Q&A and discussion Speakers: Norah Lightowler Lightowler Associates Norah Lightowler is a partner in Lightowler Associates, an independent consultancy offering regulatory advice and support to pharmaceutical companies in or proposing to enter the European market for human pharmaceuticals. They are in their twentieth year of successful business. Norah has wide experience in the pharmaceutical and related neutraceutical, herbal and devices industries as a pharmaceutical assessor with the UK regulatory authority and as associate director of European regulatory affairs with an international pharmaceutical company. She is experienced in organising and presenting courses on European regulatory control systems, including requirements, procedures and strategy. For more information about this training visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
